| Background: | Members of the solute carrier family 2 are classified as facilitative glucose transporters (GLUTs), which transport glucose into most cells. SLC2A2/GLUT2 is predominantly expressed in the liver and weakly expressed in the kidney and small intestine. Mice in which the slc2a2 gene is deleted are hyperglycemic and hypoinsulinemic; they have elevated plasma levels of glucagons, free fatty acids, and ï¢-hydroxybutyrate. Truncated forms of SLC2A2/GLUT2 that result from gene mutation are detected in patients with Fanconi-Bickel syndrome; this condition is characterized by hepatorenal glycogen accumulation, proximal renal tubular dysfunction, and impaired carbohydrate metabolism, possibly caused by dysfunction of the truncated SLC2A2/GLUT2. |
| Clonality: | Polyclonal |
| Formulation: | In PBS/50% glycerol, pH 7.2 |
| Gene ID Human: | 6514 |
| Gene ID Mouse: | 20526 |
| Host Species: | Rabbit |
| Immunogen: | Human SLC2A2-derived synthetic peptide |
| Regulatory Statement: | For Research Use Only. Not for use in diagnostic procedures. |
| Isotype: | IgG |
| Product Type: | Primary Antibody |
| Shipping: | 4 |
| Size: | 100 μL |
| Species Reactivities: | Human |
| Status: | RUO |
| Storage: | -20℃ |
| Target: | SLC2A2/GLUT2 |
Applications: FCM, IH
| FCM: | 1:500 |
| IHC: | 1:2500(Heat treatment is necessary for paraffin em |
There are no references for Anti-SLC2A2 (GLUT2) (Human) pAb at this time.